SRES.97 - A Resolution Expressing The Sense Of The Senate That The Food And Drug Administration Should Encourage The Use Of Abuse-deterrent Formulations Of Drugs.

Send your vote to Congress

My Vote

{{ my_vote|capitalize }}

My Vote

{{ bill_vote.meta.gov_vote|capitalize }}

Congress Vote

{{ bill_vote.meta.user_vote|capitalize }}

People's Vote

{{ bill_vote.meta.outcome|capitalize }}


4/15/2013--Introduced. Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

Referred To The Committee On Health, Education, Labor, And Pensions.
April 15th 2013 @ 12:00 AM

VoteTocracy Voting & Activity
Votetocracy user
{{ error }}
Votetocracy user
{{ activity.user }} in {{ activity.state }} Voted on Bill {{ activity.bill_id|billName }} {{ activity.when|howLongAgo }} Reply
{{ error }}
Govtrack Data provided by Bill analysis provided by’s analyst team.